AR113805A1 - Composiciones y métodos para tratar cáncer hepático - Google Patents
Composiciones y métodos para tratar cáncer hepáticoInfo
- Publication number
- AR113805A1 AR113805A1 ARP180103133A ARP180103133A AR113805A1 AR 113805 A1 AR113805 A1 AR 113805A1 AR P180103133 A ARP180103133 A AR P180103133A AR P180103133 A ARP180103133 A AR P180103133A AR 113805 A1 AR113805 A1 AR 113805A1
- Authority
- AR
- Argentina
- Prior art keywords
- compositions
- methods
- liver cancer
- treat liver
- pembrolizumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan métodos y composiciones para tratar los cánceres hepáticos primarios y/o los cánceres hepáticos secundarios que usan una combinación de talimogene laherparepvec y pembrolizumab, una variante de pembrolizumab o fragmento de unión a antígeno de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762578071P | 2017-10-27 | 2017-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113805A1 true AR113805A1 (es) | 2020-06-10 |
Family
ID=64453576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103133A AR113805A1 (es) | 2017-10-27 | 2018-10-26 | Composiciones y métodos para tratar cáncer hepático |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200353022A1 (es) |
EP (1) | EP3700544A1 (es) |
JP (1) | JP2021501150A (es) |
KR (1) | KR20200078483A (es) |
CN (1) | CN111278448A (es) |
AR (1) | AR113805A1 (es) |
AU (1) | AU2018355519A1 (es) |
BR (1) | BR112020007494A2 (es) |
CA (1) | CA3075294A1 (es) |
MX (1) | MX2020003388A (es) |
SG (1) | SG11202002123XA (es) |
TW (1) | TWI817958B (es) |
WO (1) | WO2019084418A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
JP2020517715A (ja) * | 2017-04-28 | 2020-06-18 | メルク・シャープ・エンド・ドーム・コーポレイション | がん療法のためのバイオマーカー |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
LT2691112T (lt) | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
WO2014036412A2 (en) | 2012-08-30 | 2014-03-06 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
US10555981B2 (en) * | 2014-07-16 | 2020-02-11 | Transgene S.A. | Oncolytic virus for expression of immune checkpoint modulators |
CN106999577B (zh) * | 2014-07-16 | 2021-12-21 | 特兰斯吉恩股份有限公司 | 溶瘤病毒和免疫检查点调节因子组合 |
BR112017025562A2 (pt) | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
US11497781B2 (en) * | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
CN110381997A (zh) * | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
JP2020517715A (ja) * | 2017-04-28 | 2020-06-18 | メルク・シャープ・エンド・ドーム・コーポレイション | がん療法のためのバイオマーカー |
-
2018
- 2018-10-26 KR KR1020207008272A patent/KR20200078483A/ko not_active Application Discontinuation
- 2018-10-26 AR ARP180103133A patent/AR113805A1/es unknown
- 2018-10-26 CA CA3075294A patent/CA3075294A1/en active Pending
- 2018-10-26 SG SG11202002123XA patent/SG11202002123XA/en unknown
- 2018-10-26 AU AU2018355519A patent/AU2018355519A1/en active Pending
- 2018-10-26 EP EP18807758.0A patent/EP3700544A1/en active Pending
- 2018-10-26 US US16/759,476 patent/US20200353022A1/en not_active Abandoned
- 2018-10-26 BR BR112020007494-2A patent/BR112020007494A2/pt unknown
- 2018-10-26 MX MX2020003388A patent/MX2020003388A/es unknown
- 2018-10-26 WO PCT/US2018/057731 patent/WO2019084418A1/en active Application Filing
- 2018-10-26 JP JP2020523323A patent/JP2021501150A/ja active Pending
- 2018-10-26 CN CN201880068853.5A patent/CN111278448A/zh active Pending
- 2018-10-29 TW TW107138162A patent/TWI817958B/zh active
Also Published As
Publication number | Publication date |
---|---|
EP3700544A1 (en) | 2020-09-02 |
JP2021501150A (ja) | 2021-01-14 |
SG11202002123XA (en) | 2020-04-29 |
US20200353022A1 (en) | 2020-11-12 |
WO2019084418A1 (en) | 2019-05-02 |
TWI817958B (zh) | 2023-10-11 |
CA3075294A1 (en) | 2019-05-02 |
BR112020007494A2 (pt) | 2020-11-03 |
CN111278448A (zh) | 2020-06-12 |
RU2020111709A3 (es) | 2022-04-26 |
MX2020003388A (es) | 2020-08-03 |
AU2018355519A1 (en) | 2020-03-26 |
KR20200078483A (ko) | 2020-07-01 |
RU2020111709A (ru) | 2021-11-29 |
TW201922273A (zh) | 2019-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
CO2017012342A2 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
CO2017010618A2 (es) | Anticuerpos contra icos | |
AU2017348322A8 (en) | Compositions and methods for treating EZH2-mediated cancer | |
EP4302835A3 (en) | Methods of treating ovarian cancer | |
BR112017023821A2 (pt) | moduladores de k-ras | |
BR112017017700A2 (pt) | métodos, composições e kits para tratamento do câncer | |
PE20170680A1 (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
CO2017003005A2 (es) | Anticuerpos anti-mfi2 | |
PH12017501879A1 (en) | Methods for treating cancer | |
CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
MX2020006297A (es) | Variantes de cd19. | |
PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
DK3478284T3 (da) | Forbindelser og sammensætninger til behandling af cancer | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
BR112018005331A2 (pt) | inibidores de pcna | |
BR112017022269A2 (pt) | métodos para tratar câncer | |
AR113805A1 (es) | Composiciones y métodos para tratar cáncer hepático | |
EA201691896A1 (ru) | Соединения и способы их применения | |
BR112018013928A2 (pt) | composições terapêuticas e métodos para tratamento da hepatite b | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
MX2019003311A (es) | Metodos para tratamiento de cancer de ovario. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |